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Aim We previously showed that cellular repressor of E1A-stimulated genes (CREG) is up-regulated during
serum starvation-induced vascular smooth muscle cell (SMC) differentiation. The aim of this study was
to determine the role of CREG in maintaining the quiescent, differentiated phenotype of SMCs both in
culture and in balloon-injured rat carotid artery.
Methods and results In cultured SMCs recombinant virus-mediated CREG expression enhanced cellular
differentiation, inhibited proliferation, and reduced synthesis of extracellular matrix component ﬁbro-
nectin. In contrast, CREG knockdown via retroviral transfer of short hairpin RNAs abrogated serum
starvation-induced SMC differentiation and growth arrest. Both immunostaining and Western analysis
demonstrated marked down-regulation of CREG in the vascular media after balloon injury to the rat
carotid artery. Retrovirus-mediated CREG transfer to the injured artery inhibited SMC dedifferentiation
and proliferation, and reduced neointimal hyperplasia.
Conclusion These results suggest that CREG participates in the maintenance of quiescent mature SMC
phenotype in the arterial media by promoting SMC differentiation and growth arrest and that CREG gene
transfer has therapeutic potential for vascular diseases associated with neointimal hyperplasia.
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1. Introduction
In the normal adult artery, smooth muscle cells (SMCs) are
highly specialized for contraction through which they regu-
late vascular tone and blood distribution. To fulﬁll this func-
tion, mature SMCs adopt an elongated morphology, remain
quiescent in proliferation and metabolism of extracellular
matrix (ECM), and express a unique repertoire of contractile
proteins, agonist receptors, and ion channels. In contrast,
SMCs within acute vascular lesions often display a stellate
shape, express fewer contractile proteins, and are active
in proliferation, migration, and ECM turnover.
1–4 A large
body of evidence has demonstrated that the SMCs in
the neointima formed after vascular injury mainly come
from the vascular media through phenotypic modulation/
switching, whereby they lose their differentiation markers
and gain the abilities to migrate, proliferate, and metab-
olize ECM. Such phenotypic modulation is fundamental to
vascular adaptation and repair as well as the development
of neointima hyperplasia. The latter is a key pathologic
feature of atherosclerosis and angioplasty-induced
restenosis.
Despite numerous studies on growth factors and cytokines
that stimulate the conversion of quiescent contractile SMCs
to aggressive proliferative ones after vascular injury, rela-
tive little is known about soluble factors that promote SMC
re-differentiation and growth arrest after vascular repair.
The latter is an essential step of the normal healing
process and is vital to limiting lesion development. We and
others have shown that cellular repressor of E1A-stimulated
genes (CREG), a secreted glycoprotein, is signiﬁcantly
up-regulated at both the mRNA and protein level during
the phenotypic conversion of proliferative SMCs to quiescent
differentiated ones.
5,6 CREG has been shown to act as a
transcription repressor to antagonize transcription acti-
vation and cellular transformation induced by the adenoviral
E1A oncoprotein.
7 The human homolog contains 220 amino
acid residues and 3 consensus N-glycosylation sites.
8,9 The
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 mannose-6-phosphate/insulin-like growth factor II receptor
(M6P/IGF2R) in a far Western analysis.
9 M6P/IGF2R is sca-
venger receptor that facilitates the clearance of extracellu-
lar IGFs, which are implicated in the pathogenesis of
atherosclerosis and restenosis.
10,11 When overexpressed in
human embryonal carcinoma cells, CREG enhances cellular
differentiation and inhibits cell cycle progression.
8
However, CREG’s biological activity in vascular cells and its
role in vascular repair remain unknown. To test the hypoth-
esis that CREG might participate in the maintenance of SMCs
in mature phenotype in the arterial media, we performed
gain- and loss-of-function analyses of CREG in cultured
SMCs. We demonstrate that CREG overexpression inhibits
SMC proliferation and promotes cellular differentiation,
whereas its knockdown prevents serum starvation-induced
SMC maturation and growth arrest. Furthermore, CREG is
down-regulated in the vascular media after balloon injury
to the rat carotid artery. Retrovirus-mediated CREG
expression in the injured artery decreases SMC proliferation,
attenuates SMC dedifferentiation, and reduces neointimal
hyperplasia. These data demonstrate for the ﬁrst time
that CREG plays a critical role in the maintenance of the dif-
ferentiated SMC phenotype and that CREG gene transfer has
therapeutic potential for vascular diseases associated with
neointimal thickening such restenosis after angioplasty.
2. Methods
2.1 Production of infectious retrovirus
Human CREG cDNA was subcloned from the pRC/CMV-hCREG (kindly
provided by Dr Grace Gill of Harvard Medical School) into the pLNCX
retroviral vector (Clontech). Green ﬂuorescent protein (GFP) cDNA
was subcloned from pEGFP-N1 (Clontech) to pLNCX. Three retroviral
vectors containing short hairpin RNAs (shRNAs) targeting to the open
reading frame of human CREG were purchased from Open Biosys-
tems (Huntsville, AL). To generate infectious retrovirus, 5 mgo f
the plasmid was transfected into Phoenix amphotropic 293 packa-
ging cells (Obigen) by calcium phosphate/DNA co-precipitation.
The conditioned medium was collected 48 h after transfection and
cell debris was removed by centrifugation and ﬁltration through
0.4-mm ﬁlters. The titer of GFP-expressing virus was determined
by infection of conﬂuent NIH3T3 cells and ﬂow cytometry.
12,13 The
CREG retrovirus was produced in parallel with and used at same con-
centrations as the GFP virus. For transient transduction of primary
SMC cultures, the CREG cDNA was subcloned into the shuttle
plasmid pShuttle-CMV-IRES-GFP at KpnI and XhoI restriction sites
and transferred to the pAdEasy adenoviral vector (Stratagene)
through bacterial homologous recombination. Recombinant adeno-
virus was produced in Ad-293 cells. Viral titer was determined
by TCID50 method. Adenovirus expressing GFP alone was prepared
as control.
2.2 Generation of CREG-overexpressing and
knockdown smooth muscle cell lines
Rat vascular SMCs were isolated by enzymatic digestion of the thor-
acic aorta with the endothelium and the adventitia mechanically
removed as previously described.
14 SMCs were cultured directly on
plastic without substrate coating and maintained in Dulbeco’s modi-
ﬁed Eagle medium (Invitrogen) supplemented with 10% fetal bovine
serum (FBS; Invitrogen), 4 mmol/L glutamine, 100 U/mL penicillin,
and 100 U/mL streptomycin (complete medium). The retrovirus
was added to the cells with multiplicity of infection (MOI) of
20 pfu/cell (viral titer based on pLNCX-GFP) in complete
medium plus polybrene (8 mg/mL) for 72 h. Stable cell lines were
established by selection with 500 mg/mL G418 for 2 weeks.
For transient CREG expression, primary SMCs were infected with
adenovirus with MOI of 300 pfu/cell for 12 h. Cell lysates were
harvested for Western analysis. To generate CREG knockdown
SMCs, human SMCs were isolated from unused segments of the
internal thoracic artery retrieved for coronary bypass surgery as
previously described.
15 The cells were infected with retrovirus
expressing CREG shRNAs produced as described above and selected
with 6 mg/mL puromycin. CREG knockdown was evaluated by
Western analysis with an anti-CREG antibody (R&D Systems). The
irrelevant b-actin served as control.
2.3 Immunoprecipitation and Western blot analysis
For immunoprecipitation, SMCs were disrupted in lysis buffer (1%
NP-40, 50 mM Tris, pH 7.4, 100 mM NaCl plus Sigma protease inhibi-
tor cocktail) and incubated with an anti-CREG monoclonal antibody
(mAb) followed by protein G agarose beads. The immunoprecipitate
was then analysed by Western blotting. For Western blotting, SMC
lysates or homogenates of rat aortic tissues were prepared in lysis
buffer containing 1% SDS. Proteins were resolved in
SDS-polyacrylamide gels and transferred to PVDF membranes. The
primary antibodies used were as follows: anti-smooth muscle (SM)
a-actin mAb (mAb 1A4, Sigma), anti-Ki67 mAb (BD Biosciences),
anti-cleaved caspase-3 (Cell signaling Biotechnology), anti-desmin
mAb, anti-pERK, anti-ERK, and anti-b-actin antibodies, and
anti-SM myosin heavy chain (SM-MHC) mAb speciﬁc to SM1 and
SM2 (Santa Cruz Biotechnology). The speciﬁc binding was detected
with horseradish peroxidase (HRP) conjugated secondary antibodies
and enhanced chemiluminascence reagents. The blots were quanti-
ﬁed on a Bio-Rad gel documentation system.
2.4 Cell cycle and cell proliferation analysis
Cell cycle analysis was carried out in SMCs serum-starved for 72 h
and then stimulated with medium containing 10% serum for 36 h.
After ethanol ﬁxation and propidium iodide staining, SMCs in dis-
tinct cell cycles were analysed by ﬂuorescence-activated cell
sorting (FACS, FACSCalibur, BD Biosiences). In order to identify repli-
cating cells, we performed bromide deoxyuridine (BrdU) incorpor-
ation assay with a cell proliferation kit (GE Healthcare Life
Sciences). Cultured SMCs were incubated with BrdU for 3 h prior
to ﬁxation. Incorporated BrdU was detected immunohistochemically
with an anti-BrdU antibody.
2.5 Balloon injury to rat carotid arteries
and retroviral transduction
Male Sprague Dawley rats (360–450 g) were anesthetized by intra-
peritoneal injection of pentobarbital sodium (30 mg/kg). The left
carotid artery was injured by a 2F Fogarty balloon embolectomy
catheter (Baxter) as previously described.
16,17 Immediately after
the balloon injury, 500 ml of Pluronic F127 (BASF Corporation) con-
taining pLNCX-CREG or pLNCX-GFP retrovirus (concentrated from
20 mL conditioned medium by ultracentrifugation, viral titer
10
7pfu/mL as determined for pLNCX-GFP retrovirus), or Pluronic
gel alone was placed around the carotid artery at the site of the
injury. The rats were sacriﬁced with an overdose of pentobarbital
sodium (100 mg/kg) at 2, 4, 7, 14, and 28 days (ﬁve animals for
each time point) after balloon injury and retroviral infection. The
uninjured right carotid arteries served as control. The experimental
procedures and animal care were approved by the Institutional
Animal Care and Use Committee of Shenyang Northern Hospital
and Robert Wood Johnson Medical School. The investigation con-
forms with the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH Publication
No. 85-23, revised 1996).
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 2.6 Immunohistochemistry and morphometric
analysis
The injured and the control carotid arteries were harvested at
designated time points and ﬁxed with 4% paraformaldehyde. The
endogenous peroxidase activity was quenched with 0.3% H2O2 and
non-speciﬁc binding sites blocked with 10% goat serum. The
primary antibody was applied for 24 h at 48C, followed by incubation
with a HRP-conjugated secondary antibody (Santa Cruz Biotechnol-
ogy) for 1 h at room temperature. Colour development was achieved
with the DAB chromogen system (Dako). The aortic sections were
counterstained with hematoxylin, examined on an Olympus IX70
microscope, and photographed with a CoolSNAP-Profx camera
(Media Cybernetics). For morphometric analysis of neointimal for-
mation, sections were stained with hematoxylin–eosin, photo-
graphed and analysed using image analysis software
(Image-proplus 5.1, Olympus). The area of the intima, media, and
adventitia was measured, and the intima /media ratio was
calculated.
2.7 Statistical analysis
The data were expressed as mean+SEM. Statistical signiﬁcance
between two groups was compared by an unpaired Student’s
t-test. Differences between multiple groups were analysed by
ANOVA.
3. Results
3.1 CREG overexpression inhibits smooth muscle
cell proliferation and enhances cellular
differentiation
We previously showed that CREG expression closely corre-
lates with the proliferative and differentiation status of cul-
tured vascular SMCs.
5 To test the hypothesis that CREG
might regulate SMC phenotypic switching from a less differ-
entiated, proliferative state to a quiescent differentiated
state, we generated stable rat vascular SMCs overexpressing
CREG by infecting the cells with retroviral vector
pLNCX-CREG. As demonstrated in Figure 1, pLNCX-CREG
transduction caused a 3-fold increase in CREG
protein expression compared with the untreated and GFP-
transduced SMCs. The GFP-transduced cells assumed
spread morphology when cultured in 5% FBS. In contrast,
those overexpressing CREG converted to a spindle shape, a
characteristic of the mature SMC phenotype. In addition,
Western analysis revealed that SMC differentiation markers
SM a-actin and desmin were markedly up-regulated in CREG-
transduced SMCs. To examine whether the enhanced SMC
differentiation might be coupled with cell proliferation,
we performed FACS analysis and BrdU incorporation assay.
CREG overexpression resulted in signiﬁcant retention
of SMCs in the G0/G1 phase when compared with the
untreated and GFP-transduced cells (P , 0.01). Moreover,
there was a 4-fold reduction in BrdU incorporation in
CREG-overexpressing SMCs (P , 0.01 compared with
untreated and GFP-expressing cells). These data demon-
strate that CREG overexpression leads to cellular differen-
tiation and growth suppression in SMCs.
SMCs enzymatically dissociated from the arterial media
rapidly undergo phenotypic modulation and lose some of
their differentiated characteristics when cultured on
plastic in serum-containing medium, especially after sub-
culturing. This is reﬂected by the disappearance of
SM-MHC and increased synthesis of the ECM protein ﬁbro-
nectin. To determine whether CREG might inhibit the SMC
dedifferentiation process, we overexpressed CREG in
primary SMC cultures via adenoviral gene transfer.
Western analysis of CREG-transduced cells with CREG-
speciﬁc antibodies detected four bands migrating
between 25–35 kDa, which likely represent differentially
glycosylated CREG as treatment of cell lysates with gly-
cosidase F downshifted the higher bands (Figure 1F,
data not shown). Importantly, forced CREG expression
caused a 2-fold increase of SM-MHC content (P , 0.05
compared with untreated and GFP-expressing cells)
and a 3-fold reduction of cell-associated ﬁbronectin
(P , 0.01 compared with untreated and GFP-expressing
cells) indicating that CREG promotes the differentiated
SMC phenotype.
Figure 1 CREG overexpression in vascular smooth muscle cells promotes
cellular differentiation and inhibits proliferation. (A) Rat SMCs were infected
with retrovirus pLNCX expressing CREG (pL0-CREG) or GFP (pL0-GFP) and
stable cell lines were established by G418 selection. Cell lysates were ana-
lysed by Western blotting for CREG expression. b-actin serves as loading
control. NT, no treatment. (B) Phase-contrast micrographs of SMCs stably
transduced with CREG or GFP. CREG-expressing SMCs display a spindle-shaped
morphology. (C) SMC differentiation markers SM a-actin and desmin were
detected by Western analysis. b-actin serves as loading control. (D) SMCs
were serum-starved for 72 h and then replaced with medium containing
10% serum for 36 h, ﬁxed, stained with propidium iodide, and analysed by
ﬂuorescence-activated cell sorting. The percentage of SMCs in different
cell cycles is depicted with bar graph. pL0-CREG vs. NT or pL0-GFP in G0/G1
and G2/M phase, **P , 0.01, n ¼ 5. (E) SMCs were labeled with bromide deox-
yuridine (BrdU) for 3 h, ﬁxed and immunostained with a BrdU speciﬁc anti-
body. BrdU positive cells were counted and plotted. pL0-CREG vs. NT and
pL0-GFP, **P , 0.01. n ¼ 5. (F) Primary cultures of rat vascular SMCs were
infected with adenovirus expressing GFP (Ad-GFP) or CREG (Ad-CREG) for
24 h. Cell lysates were analysed by Western blotting for CREG, smooth
muscle myosin heavy chain (SM-MHC), and ﬁbronectin. b-actin serves as
loading control.
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 3.2 CREG mediates serum starvation-induced
smooth muscle cell differentiation
and growth arrest
We have reported that serum reduction can convert human
SMCs from a proliferative, synthetic state to a quiescent,
contractile state, and that CREG is up-regulated in this
process.
5 To determine whether CREG might mediate this
phenotypic transition, we suppressed CREG expression in
human SMCs via retroviral transfer of shRNAs that target
t ot h eo p e nr e a d i n gf r a m eo fh u m a nC R E G .A ss h o w ni n
Figure 2,s t a b l ee x p r e s s i o no fs h R N A si nt h eS M C s
reduced CREG protein expression by 80% compared with
the control vector-transduced cells (P , 0.01). CREG in
SMC lysates displayed double bands, possibly due to differ-
ent levels of glycosylation. To assess the effect of CREG
knockdown on serum deprivation-induced SMC differen-
tiation, we performed Western analysis for SMC contractile
protein SM a-actin. Control SMCs cultured in serum-free
medium for 3 days signiﬁcantly up-regulated their SM
a-actin expression (Figure 2B). In contrast, stable
expression of CREG shRNAs blocked serum
deprivation-induced SM a-actin expression (control vs.
shRNA1 P , 0.01, control vs. shRNA2 P , 0.05). We also
observed enhanced cell cycle progression from the G0/G1
phase to the S and G2/M phase after shRNA-mediated
CREG suppression. Taken together, these results suggest
that CREG plays a critical role in serum
withdrawal-induced SMC maturation as evidenced by
enhanced cellular differentiation and reduced
proliferation.
3.3 CREG expression closely correlates with the
proliferative and differentiation status of smooth
muscle cells within the artery wall
CREG has been shown to be ubiquitously expressed in human
and mouse tissues.
7,8 However, its physiological functions
and possible involvement in pathological processes remain
unknown. We have observed enhanced CREG expression in
cultured vascular SMCs as they convert from an aggressive
proliferative to a quiescent mature phenotype. To deter-
mine whether CREG might also be expressed in SMCs in
the arterial media and whether its expression might corre-
late with SMC phenotypic modulation, we introduced
balloon injury to the rat carotid artery and harvested the
injured arteries on days 2, 4, 7, 14, and 28 which span
the period during which SMCs dedifferentiate, form an
intimal lesion, and then re-differentiate as the lesion sub-
sides. Immunohistochemistry revealed that CREG was
expressed in the medial SMCs of normal arteries and was
markedly down-regulated in the ﬁrst week after the
balloon injury, with close correlation to the SMC dedifferen-
tiation process (reduction in SM a-actin and SM-MHC and
increase in Ki67, a proliferation marker). After 7 days, the
neointima started to form and CREG expression gradually
restored in both the newly formed neointima and the
media as the SMCs began to re-differentiate (Figure 3).
Figure 2 shRNA-mediated CREG knockdown in smooth muscle cells inhibits cellular differentiation and enhances proliferation. Human SMCs were stably trans-
duced with short hairpin (sh) RNAs targeting to the open reading frame of human CREG (shRNA1 and shRNA2) or the empty vector (control). (A and A0) CREG
secreted by the SMCs to the culture medium was analysed by immunoprecipitation (IP) followed by immunoblotting (IB) with a CREG-speciﬁc antibody. CREG
in cell lysates was directly examined by IB. b-actin serves as loading control. CREG protein expression was quantiﬁed by densitometry and plotted as the
ratio of CREG to b-actin. Control vs. shRNA1 and shRNA2 in both medium and the cell lysates, **P , 0.01, n ¼ 3. (B and B0) The expression of the differentiation
marker SM a-actin was determined by IB before and after serum starvation and quantiﬁed by densitometry. The expression level is depicted as the ratio of SM
a-actin to b-actin. Control vs. shRNA1 **P , 0.01, control vs. shRNA2, *P , 0.05 under serum deprivation conditions, n ¼ 3. (C) Cell cycle progression was
assessed by ﬂuorescence-activated cell sorting analysis.
Y. Han et al. 600
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 Western analysis demonstrated a similar trend in the
expression of CREG and contractile proteins (P , 0.05). In
the course of the lesion formation, CREG levels inversely
correlated with SMC proliferation as revealed by Ki67 stain-
ing. These data strongly suggest that CREG is associated
with the quiescent mature SMC phenotype, and that the
injury-induced CREG down-regulation may facilitate SMC
dedifferentiation and lesion formation.
3.4 Retrovirus-mediated CREG gene transfer to the
balloon-injured artery inhibits neointimal formation
Since CREG induces cultured SMCs to adopt a more
differentiated phenotype, and since CREG is down-
regulated in the arterial media in parallel with enhanced
SMC proliferation and dedifferentiation after vascular
injury, we hypothesized that forced expression of CREG
in the injured vessel wall might promote SMC differen-
tiation, inhibit cell proliferation, and thus reduce neointi-
mal formation. To test this hypothesis, we delivered CREG-
or GFP-expressing retrovirus to the balloon-injured carotid
artery using Pluronic gel, which has been widely employed
as a carrier to deliver viral vectors and other agents to
arteries.
18,19 Immunohistochemistry and ﬂuorescent
microscopy detected high levels of GFP or CREG expression
in the artery wall up to 28 days after balloon injury
(Figure 4, data not shown). In comparison with the
untreated control and GFP-transduced arteries, infection
of the injured arteries with retroviral CREG markedly
increased CREG levels as assessed by Western blotting
(P , 0.05). Histological analysis of the injured arteries
revealed that retrovirus-mediated CREG transfer signiﬁ-
cantly decreased the neointimal area (CREG vs. GFP or
untreated control group, P , 0.01) and the intima to
media ratio (CREG vs. GFP or untreated control group,
P , 0.05), indicating that CREG may participate in the
maintenance of quiescent mature SMC phenotype in the
arterial media and that the restoration of CREG expression
by retroviral transduction reduces neointimal hyperplasia
after acute vascular injury (Figure 5).
Figure 3 CREG expression in normal and balloon-injured rat carotid arteries
and its correlation with smooth muscle cell differentiation and proliferation.
(A) The segments of the rat carotid artery were harvested at designated time
points after balloon injury, ﬁxed and immunostained for CREG, SM a-actin,
SM-MHC, and the proliferation marker Ki67. CREG expression correlates posi-
tively with those of SM a-actin and SM-MHC, and negatively with that of Ki67
in the artery wall during vascular repair. (B and B0) Western analysis of arter-
ial homogenates was performed for CREG, SM a-actin, SM-MHC before and
after vascular injury. The blots were scanned by densitometry and plotted
as the ratio of CREG, SM a-actin, or SM-MHC to b-actin. Day 0 vs. day 2, 4,
and 7 for CREG expression, **P , 0.01; day 0 vs. day 2 and 4 for SM
a-actin expression, *P , 0.05; day 0 vs. day 2 and 4 for SM MHC expression,
**P , 0.01; n ¼ 5.
Figure 4 Retroviral delivery of CREG to the injured arteries. Immediately
after balloon injury to the rat carotid artery, pluronic gel containing CREG-
or GFP-expressing retrovirus was applied to the adventitial side of the
injured artery. (A) Fluorescent micrographs of tissue sections show GFP
expression 2 days after balloon injury in the neointima and the arterial
media of retrovirus pLNCX-GFP transduced arteries, but not those infected
with pLNCX-CREG. (B) Immunostaining for CREG in pLNCX-CREG and
pLNCX-GFP transduced rat carotid arteries 2 days after balloon injury. (C)
CREG expression was analysed by Western blotting in the uninjured and
balloon-injured arteries infected with retroviral vectors pLNCX-CREG or
pLNCX-GFP. b-actin serves as loading control. pLNCX-CREG vs. untreated
injured control and pLNCX-GFP, *P , 0.05. n ¼ 5 for each group.
CREG inhibits neointimal formation 601
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 3.5 Retrovirus-mediated CREG gene transfer to the
injured artery inhibits smooth muscle cell
dedifferentiation, proliferation, and extracellular
signal-related kinase activation
Numerous studies have suggested that neointimal hyper-
plasia after acute vascular injury results from the dediffer-
entiation of SMCs in the media and their subsequent
migration to and proliferation in the intima.
20 To deter-
mine whether retroviral transfer of CREG to the injured
arterial wall might inhibit SMC proliferation and enhance
cellular differentiation, we examined the expression of
SMC differentiation markers SM-MHC and SM a-actin by
Western blotting. Tissue homogenates of 4-day post-injury
arteries had a 50% reduction of SM-MHC and SM a-actin in
the untreated and GFP-transduced vessels (CREG vs. GFP
or untreated control group, P , 0.01) (Figure 6,d a t an o t
shown). Of note, the mature type of SM-MHC SM2 was com-
pletely disappeared. In contrast, CREG transduction atte-
nuated the reduction of these contractile proteins in the
injured artery. Furthermore, SMC proliferation in CREG-
transduced arteries was signiﬁcantly inhibited as evi-
denced by reduced Ki67 positive cells in the neointima
and the media. These results suggest that CREG partici-
pates in the maintenance of the quiescent, mature SMC
phenotype in the vascular media and that CREG gene trans-
f e rm a yh a v et h e r a p e u t i cp o t e n t i a lf o rv a s c u l a rd i s e a s e s
associated with SMC dedifferentiation and neointimal
hyperplasia.
To determine whether the reduced neointimal formation
by CREG transduction might also result from induction of
apoptosis, we immunostained 4-day post-injury arteries for
cleaved (active) caspase-3, a marker for apoptosis. As
demonstrated in Figure 6C, many positive cells were
Figure 6 Retrovirus-mediated CREG expression suppresses smooth muscle
cell proliferation, induces cellular differentiation, and inhibits apoptosis
and ERK activation in balloon-injured rat carotid arteries. (A and A0) The
left carotid artery was harvested 4 days after balloon injury and retroviral
infection. The expression of SM a-actin and SM-MHC was quantiﬁed by
Western blot analysis. Balloon injury induced disappearance of the mature
form of SM-MHC SM2 and down-regulation of SM1 and SM a-actin, whereas
forced CREG expression restored their expression. The blots were quantiﬁed
by densitometry and plotted as the ratio of SM a-actin or SM-MHC to b-actin.
pL0-CREG vs. injured and pL0-GFP, **P , 0.01, n ¼ 5. (B) The tissue sections of
injured arteries were immunostained for the proliferation marker Ki67 and
the positive cells were counted in high power ﬁelds (HPF). pLNCX-CREG trans-
duction signiﬁcantly reduced the number of Ki67-positive cells in the neoin-
tima and the media of the injured arteries. pL0-CREG vs. pL0-GFP, *P ,
0.05, n ¼ 5. (C) The 4-day injured carotid artery was harvested and immunos-
tained for cleaved caspase-3. Arrow heads point to the positively stained
cells. (D and D0) The segments of balloon-injured carotid artery were har-
vested and subject to Western analysis using antibodies to tyrosine-
phosphorylated ERK (pERK) and total ERK. Retrovirus-mediated CREG
expression inhibited ERK phosphorylation induced by balloon injury,
whereas GFP expression had no effect. Blots were quantiﬁed by densitometry
and plotted as the ratio of pERK to total ERK. pL0-CREG vs. pL0-GFP at day 2,
4, 7 time points, **P , 0.01, n ¼ 5 for each time point.
Figure 5 Retroviral delivery of CREG to the balloon-injured artery inhibits
neointimal hyperplasia. (A) Retrovirus expressing CREG or GFP was applied
to the adventitial side of balloon-injured rat carotid arteries using Pluronic
gel. The arteries were harvested at designated time points and stained
with hematoxylin and eosin. The uninjured right carotid arteries serve as
control. The arrow heads deﬁne the neointimal layer. (B) The areas of
intima and the media in the cross sections of the artery were measured mor-
phometrically and plotted. The neointima area of CREG group vs. that of NT
and GFP groups at 14 and 28 day time points, **P , 0.01. The intima/media
ratio of CREG group vs. that of NT and GFP groups at 14 and 28 day time
points, *P , 0.05, n ¼ 5 for each group.
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 identiﬁed in the media layer and the luminal surface of
untreated or GFP-transduced arteries. Surprisingly, CREG
transduction reduced apoptosis in the arterial wall after
balloon injury. These data indicate that apoptosis does not
account for reduced neointimal formation after CREG
transduction.
Mitogen-activated protein kinase (MAPK) has been impli-
cated in the development of neointima after acute vascular
injury.
21–23 To test whether CREG might modulate extra-
cellular signal-related kinases (ERK) activity in injured
arteries, we performed Western analysis using an antibody
that speciﬁcally reacts with active, tyrosine-phosphorylated
ERK1 and 2. Balloon injury to the carotid artery induced
marked activation of ERK1 and 2, which gradually returned
to the normal level after 2 weeks. Retrovirus-mediated
CREG transfer inhibited ERK activation as compared to the
GFP control (P , 0.01) (Figure 6D). These results suggest
that CREG-mediated inhibition of ERK activation after vascu-
lar injury may contribute to the reduced SMC proliferation
and neointima hyperplasia.
4. Discussion
CREG is a ubiquitously expressed protein in mammals.
However its functions in the vasculature under normal and
pathologic conditions are unknown. In this study, we demon-
strate, for the ﬁrst time, that overexpression of CREG inhi-
bits proliferation and enhances differentiation in cultured
vascular SMCs. Moreover, shRNA-mediated CREG knockdown
abrogates serum starvation-induced SMC maturation and
growth arrest. In balloon-injured rat carotid artery, CREG
expression is down-regulated in the vascular media in paral-
lel with SMC contractile proteins SM a-actin and SM-MHCs.
Forced expression of CREG in the injured arteries inhibits
SMC proliferation, attenuates SMC dedifferentiation, and
reduced neointimal formation. Retrovirus-mediated CREG
expression also inhibits the activation of MAPK pathway,
which may underlie the anti-proliferative effect of CREG.
Taken together, these results indicate that CREG plays a
critical role in the maintenance of SMCs in a mature,
growth quiescent state in the normal artery and that CREG
down-regulation contributes to neointimal hyperplasia
after vascular injury.
Under physiological conditions, SMCs in the normal adult
artery are maintained in a quiescent contractile state. Simi-
larly, SMCs switch from a migratory, proliferative, and syn-
thetic phenotype to a non-proliferative and contractile
one in the process of vascular maturation during embryonic
development as well as in the resolution phase of vascular
repair. However, it is largely unknown how this phenotypic
switching is attained and how the quiescent contractile
state is maintained in these processes. Given that a
number of growth factors including platelet-derived
growth factors, IGFs, and transforming growth factors have
been implicated in the conversion of SMCs from contractile
to synthetic phenotype, it is likely that growth factor with-
drawal may lead to the acquisition of the quiescent contrac-
tile state. Another possibility is the active secretion of
soluble factors and ECM proteins that stimulate the phenoty-
pic switching. Small et al.
6 has recently shown that CREG
mRNA is signiﬁcantly up-regulated during the conversion of
a human vascular SMC line from non-contractile to contrac-
tile state. We have also shown that in serum
starvation-induced differentiation of conﬂuent vascular
SMCs, CREG protein expression is increased in parallel with
smooth muscle contractile proteins SM a-actin and calpo-
nin.
5 In the present study, we utilized both gain- and
loss-of function analysis to determine the biological activity
of CREG in vascular SMCs and its role in serum
starvation-induced SMC differentiation and growth suppres-
sion. We found that CREG overexpression converted SMCs
from a spread to a spindle shape and enhanced the
expression of SM a-actin, desmin, and SM-MHC, indicating
that CREG promotes a quiescent mature phenotype in
SMCs. The knockdown study has conﬁrmed this notion,
demonstrating that CREG suppression attenuated serum
starvation-induced SM a-actin expression and growth
arrest. This result suggests that CREG mediates serum
starvation-induced SMC maturation. Our data are in agree-
ment with the observations that CREG, when overexpressed,
enhanced human embryonic carcinoma cell differentiation
and inhibited the proliferation of rat neonatal cardiomyo-
cytes.
8,24 Recently we observed that CREG knockdown
promoted cell proliferation in NIH 3T3 ﬁbroblasts (data
not shown). Since CREG is highly expressed in many
adult tissues, these ﬁndings support the hypothesis that it
may participate in the induction and maintenance of
the quiescent, differentiated cell phenotype in various
tissues.
The in vivo function of CREG has not been reported. To
determine whether CREG might also regulate SMC pheno-
type modulation in the artery wall, we introduced balloon
injury to the rat carotid artery and examined CREG
expression by immunohistochemistry and Western blot
analysis. We found that CREG was highly expressed in the
SMCs of the arterial media and the endothelium. Its
expression was signiﬁcantly decreased as SMCs dedifferen-
tiated and proliferated in the ﬁrst week after balloon
injury, and was restored to the normal levels as SMCs
re-differentiated and the lesion became quiescent. Of
note, retroviral transfer of CREG into the injured artery
wall inhibited SMC dedifferentiation and proliferation and
reduced neointimal hyperplasia. These data suggest that
CREG may play a critical role in maintaining the medial
SMCs in a quiescent contractile state in normal adult
artery and that CREG gene/protein transfer has therapeutic
potential for arterial restenosis after angioplasty. One
caveat is that in patients with restenosis intimal hyperplasia
often develops on top of atherosclerotic lesions in which
SMCs may respond differently to injury from what modeled
in this study. In the future, it is desirable to examine the
role of CREG in SMC phenotypic modulation in animal
models of acute vascular injury combined with
atherosclerosis.
Our data demonstrate that retrovirus-mediated gene
transfer leads to the restoration of CREG expression in
injured rat carotid arteries and a signiﬁcant reduction, but
not totally absence of neointimal formation. These results
suggest that overexpression of CREG alone is not sufﬁcient
to completely block neointima hyperplasia. One possible
explanation for this is that the growth suppression induced
by CREG overexpression is not enough to override the
effect of growth-stimulating factors released after vascular
injury. Another possibility is that growth inhibitors other
than CREG may also be down-regulated after vascular
injury. Thirdly, reduction of CREG receptor(s) or
CREG inhibits neointimal formation 603
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 ligand-receptor binding may also account for the incomplete
inhibition of neointima formation.
CREG was initially postulated as a transcription repressor
for the oncoprotein E1A-activated genes. Later it was found
to be a secreted glycoprotein that binds to M6P/IGF2R in a
far Western analysis.
9 M6P/IGF2R has no intrinsic signalling
transduction activity but acts as a scavenger receptor.
After binding to IGF-II and to a lesser extent IGF-I, the
receptor is internalized and degraded together with the
ligands.
25 Therefore, the IGF2R counteracts the mitogenic
effect of IGFs and thus negatively regulates cell growth.
IGFs are potent activators of MAPK pathways that mediate
IGF-stimulated cell proliferation, and have been implicated
in the pathogenesis of atherosclerosis and restenosis after
angioplasty.
10,11 In this study, we observed strong activation
of ERK1/2 immediately following vascular injury, which
gradually returned to the baseline after 2 weeks. Impor-
tantly, CREG gene transfer to the injured carotid artery sig-
niﬁcantly inhibited ERK activation. This result suggests that
the inhibition of ERK activation may be responsible for
CREG-induced SMC growth suppression and neointimal
reduction. Recently, we detected nuclear localization of
CREG in several mouse tissues by immunohistochemistry
(data not shown). This ﬁnding revitalizes the hypothesis
that CREG may act as a transcription repressor of
proliferation-related genes. Whether CREG functions as a
transcription repressor in the nucleus or a soluble ligand
for membrane receptor M6P/IGF2R is currently under
active investigation.
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